UCB – Inspired by patients. Driven by science. UCB on Twitter UCB on LinkedIn UCB on Facebook UCB Worldwide Main navigation Approach Team Portfolio News Power, Precision & Agility Where to find us BRUSSELS LONDON BOSTON About UCB Ventures UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to further strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. We make long term investments in early stage companies in the US and Europe. Our portfolio reflects our investment strategy. We invest in start-ups developing novel therapeutic modalities, platforms/assets that address novel biology, or innovative digital solutions, in areas adjacent to or even beyond UCB's current therapeutic focus. We are seeking breakthrough innovations in next generation cell and gene therapy, regenerative medicine, cell and tissue homeostasis, RNA targeted therapeutics, and patient engagement solutions that significantly improve outcomes. We are known for our speed and agility, yet thoughtful and sophisticated approach. Above all, we are committed long term investors, working closely with entrepreneurs to bring out the best in our portfolio companies. News ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19 Belgium, 1 September 2021: ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first patient has been treated in a Phase 1b/2 global clinical study of XVR011, its potent COVID-19 neutralizing antibody. read more ExeVir announces first subjects dosed in Phase I clinical study of potent COVID-19 neutralizing antibody Belgium, 18 August 2021: ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its llama-derived antibody for the treatment and prevention of COVID-19. read more ExeVir’s CRO hunt for Phase II/III COVID-19 subQ antibody trial to start midyear, also USD 50– 100m Series B raise 13 Jul 2021. ExeVir Bio will open its doors to CRO pitches mid-year for a Phase II/III trial investigating its subcutaneously administered neutralizing antibody XVR011 in outpatient COVID-19 patients, CEO Torsten Mummenbrauer said. Decisions will be made in 2H21 for a 2Q22 trial start, he added. read more Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Program, Demonstrating Significant Seizure Suppression in Model of Focal Epilepsy 18 Jun 2021. Neurona is a cell therapy company focused on the development of breakthrough treatments for neurological disorders read more ExeVir’s CRO hunt for Phase II/III COVID-19 subQ antibody trial to start midyear, also USD 50– 100m Series B raise 22 Apr 2021. ExeVir Bio will open its doors to CRO pitches mid-year for a Phase II/III trial investigating its subcutaneously administered neutralizing antibody XVR011 in outpatient COVID-19 patients, CEO Torsten Mummenbrauer said. Decisions will be made in 2H21 for a 2Q22 trial start, he added. read more Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Program, Demonstrating Significant Seizure Suppression in Model of Focal Epilepsy 19 Apr 2021. Neurona is a cell therapy company focused on the development of breakthrough treatments for neurological disorders read more StrideBio Announces Closing of $81.5M Series B Financing Research Triangle Park, N.C., Mar. 16, 2021 – StrideBio, Inc., a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the closing of an oversubscribed Series B funding round, which raised $81.5 million. read more Legal notice Cookie policy Cookie Preferences Contact us © 2019 UCB Ventures, Belgium. All rights reserved Privacy Preference Center This UCB website uses cookies. Some of these cookies are necessary for the proper functioning of this website (strictly necessary cookies) and for instance relate to managing user preferences or website security. Strictly necessary cookies cannot be refused when you choose to visit this website. We would also like to set other – optional – cookies for instance for user experience enhancement, website improvement or analytics. We will not deploy optional cookies unless you consent to their use. To grant your consent to all optional cookies at once, please click on the “Allow All” button below. If you click on “Reject All”, without specifying your preference using the toggles below, we will not set any optional cookies. For more information on which cookies we use, please read through our Cookie Policy. Strictly Necessary Cookies Always Active Performance Cookies Allow All Reject All Confirm My Choices